Zacks: Brokerages Expect Akari Therapeutics PLC (AKTX) to Post -$0.66 Earnings Per Share

Equities analysts predict that Akari Therapeutics PLC (NASDAQ:AKTX) will report earnings per share of ($0.66) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Akari Therapeutics’ earnings. Akari Therapeutics posted earnings per share of ($0.09) during the same quarter last year, which would indicate a negative year over year growth rate of 633.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, June 18th.

On average, analysts expect that Akari Therapeutics will report full-year earnings of ($1.75) per share for the current year, with EPS estimates ranging from ($2.71) to ($1.00). For the next fiscal year, analysts expect that the firm will report earnings of ($2.21) per share, with EPS estimates ranging from ($3.42) to ($1.00). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Akari Therapeutics.

Akari Therapeutics (NASDAQ:AKTX) last posted its earnings results on Wednesday, March 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.59.

Several equities research analysts have weighed in on AKTX shares. Canaccord Genuity cut their target price on shares of Akari Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, March 29th. ValuEngine upgraded shares of Akari Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Akari Therapeutics has an average rating of “Hold” and a consensus target price of $4.63.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AWM Investment Company Inc. acquired a new stake in Akari Therapeutics in the fourth quarter worth $2,962,000. Hikari Power Ltd raised its holdings in shares of Akari Therapeutics by 320.5% during the first quarter. Hikari Power Ltd now owns 636,343 shares of the biopharmaceutical company’s stock worth $1,158,000 after acquiring an additional 485,009 shares during the period. Millennium Management LLC raised its holdings in shares of Akari Therapeutics by 125.0% during the fourth quarter. Millennium Management LLC now owns 260,020 shares of the biopharmaceutical company’s stock worth $1,126,000 after acquiring an additional 144,477 shares during the period. Finally, Endurant Capital Management LP acquired a new stake in shares of Akari Therapeutics during the fourth quarter worth $871,000. Institutional investors own 18.52% of the company’s stock.

AKTX traded up $0.03 during mid-day trading on Thursday, hitting $1.89. The stock had a trading volume of 20,700 shares, compared to its average volume of 118,082. The firm has a market cap of $22.73 million, a PE ratio of -6.75 and a beta of -7.65. Akari Therapeutics has a 1-year low of $1.70 and a 1-year high of $11.95.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.

Get a free copy of the Zacks research report on Akari Therapeutics (AKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Akari Therapeutics (NASDAQ:AKTX)

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply